Why the study?
Does BMP6 plasma concentration predict all-cause mortality or CHF hospitalisation in patients with chronic heart failure?
Cohort (n=162)
Does BMP6 plasma concentration predict all-cause mortality or CHF hospitalisation in patients with chronic heart failure?
Answers are grounded in this paper and cite their sources.
BMP6 plasma levels are elevated in chronic heart failure and correlate with disease severity and congestion, but do not predict 12-month mortality or hospitalization.
Derangement of bone morphogenetic protein (BMP) signalling was observed in cardiovascular disorders. The present study assesses the diagnostic and prognostic value of BMP6 plasma concentration in chronic heart failure (CHF). 130 CHF patients and 32 controls participated in the study. BMP6 plasma level was measured at baseline. During 12-month follow-up death and hospitalisation with CHF exacerbation were recorded. BMP6 was significantly increased in CHF patients with highest concentration in most advanced disease. Individuals with pulmonary congestion or peripheral oedema had higher levels of BMP6 than isovolemic patients. BMP6 was not a predictor of all-cause mortality or CHF hospitalisation. BMP6 may be involved in pathophysiology of systolic CHF. BMP6 plasma level is related to the disease severity and signs of exacerbation.
No takes yet. Share an insight, caveat, or question.
Banach et al. (2016) conducted a cohort in Chronic heart failure (n=162). BMP6 plasma concentration vs. Controls was evaluated on All-cause mortality or CHF hospitalisation.
Synapse has enriched 10 related papers. Consider them for comparative context: